Generics

Press enter to search
Close search
Open Menu

Generics

News and information on generic drugs sold in retail pharmacies, as well as their suppliers.

Q&A: Dr. Reddy's Vaishnav discusses the company's pharmacovigilance efforts

Foram Vaishnav, who leads North American pharmacovigilance and safety for Dr. Reddy's, spoke to DSN about what it takes to keep the pharma supply chain safe.

Colored pills.

Sol-Gel Technologies, Perrigo to collaborate on 3 new generics

Sol-Gel and Perrigo's collaboration on generics now covers 10 products.

Approximately 99.6% of votes cast by Mylan shareholders were voted in favor of the proposed combination of Mylan and Upjohn.

Colored pills.

Rivaroxaban tablets — 10 mg, 15 mg and 20 mg — had a market value of $6.1 billion for the 12 months ended March 2020, according to IQVIA.

Propafenone hydrochloride extended-release capsules had a market value of roughly $51 million for the 12 months ended May 2020, according to IQVIA.

Mexiletine hydrochloride has a market value of roughly $16 million, according to IQVIA.

Zydus Cadila’s generic Antivert tablets provide treatment for symptoms associated with motion sickness and vertigo.

Bausch + Lomb will be responsible for sales, marketing, and other commercialization efforts for biosimilar Lucentis, following regulatory approval in the United States and Canada.

Money with colored pills on it.

The Increasing Access to Biosimilars Act would direct the Department of Health and Human Services to create a shared savings demonstration program for biosimilar drugs in the Medicare program, which will help increase competition and expand access.

A hand holding a generic pill bottle.

The Association for Accessible Medicines is inviting Americans to shoot and submit 10- to 30-second videos about their experiences obtaining their prescriptions during COVID-19.

A hand holding a white pill bottle.

The ethacrynic acid tablet had a market value of roughly $17 million for the 12 months ended April 2020, according to IQVIA.

Fresenius Kabi’s Simplist MicroVault packaging supports diversion deterrence and secure dispensing of controlled substances.

A pill bottle in a blue background with no words on it.

The Zytiga brand and generic had a market value of approximately $454 million for the most recent 12 months ended March 2020, according to IQVIA.

Pills spilling from a vial.

The FDA has revoked its emergency use authorization for the drugs to treat COVID-19 based on results from a large clinical trial that showed no benefit for decreasing death or speeding recovery.

A hand signing a document.

Dr. Reddy's is acquiring Wockhardt's branded generics, which include respiratory, neurology, VMS, dermatology, gastroenterology, pain and vaccines.

Novartis is launching generic Afinitor tablets in dosage strengths of 2.5 mg, 5 mg and 7.5 mg.

Leucadia’s dihydroergotamine mesylate nasal spray is the first generic of Bausch Health’s Migranal.

Injectable vials.

The product, a "follow-on" biologic of Sanofi's Lantus, has been approved in both vial and prefilled pen presentations.

Pills coming out of a bottle.

Zydus Cadila’s generic Jadenu will be available in dosage strengths of 90 mg, 180 mg and 360 mg.

Various pill bottle with white pills.

AAM welcomed testimony in which U.S. Trade Representative Robert Lightizer said the free trade agreement currently being negotiated will not contain a provision requiring 10-years of biologic exclusivity.

Tecfidera had a market value of roughly $3.78 billion for the 12 months ended April 30, according to IQVIA.

Meloxicam capsules had a market value of roughly $14 million, according to IQVIA data from March.

A white pill bottle.

The Colcrys brand and generic had a market value of approximately $491 million for the most recent 12 months ended March 2020, according to IQVIA.

A document being signed.

Akorn said it will continue to operate as usual throughout the duration of the Chapter 11 and sale process, including meeting its contractual obligations and making payments to vendors.

Pill bottles on a pharmacy shelf.

The Oseltamivir phosphate brand and generic had a market value of roughly $188 million, while the dofetilide brand and generic had a market value of more than $63.4 million.

A pill bottle with tablets.

Everolimus tablets had a market value of roughly $435 million in the 12 months endedApril 2020, according to IQVIA.

Show More